Please login to the form below

Not currently logged in
Email:
Password:

Crestor patent legal battle looms

AstraZeneca is preparing for the start of a legal battle to protect the patent on Crestor.
AstraZeneca will go to court next week to lay out a case against generic challengers, which want to start making cheap copies of the cholesterol-lowering product as early as the middle of next year.

Crestor, which is seen as AstraZeneca's big hope for the next five years, generated sales of $3.6bn (£2.2bn) last year. Analysts think this will rise to $6.7bn by 2014, making it an important revenue earner. The main patent covering the drug's chemical formula is due to run out in the US in 2016.

The launch of a generic alternative would wipe out about a quarter of Crestor's total market value. Precedent, however, is on AstraZeneca's side as similar cases involving Seroquel and Nexium, two of its other key products, were settled in its favour last year.

9th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics